Singapore, a nation recognized globally for its remarkable achievements in extending human lifespan, is simultaneously confronting a significant public health challenge: the prevalence of prolonged periods of ill-health in the twilight years of life. This burgeoning concern has spurred dedicated research efforts at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), where scientists are exploring innovative avenues to counteract the detrimental effects of aging itself, with a particular focus on preventing and treating age-associated neurodegenerative conditions such as Alzheimer’s disease. The overarching aim is to transition from merely managing symptoms of diseases to actively intervening in the fundamental biological processes that drive aging and its associated ailments.
In a groundbreaking study published in the esteemed scientific journal Aging Cell, a team of researchers, spearheaded by Professor Brian K. Kennedy, Chair of the Healthy Longevity Translational Research Programme (TRP) and a distinguished figure in the Department of Biochemistry at NUS Medicine, has identified a compound with significant therapeutic potential. This compound, calcium alpha-ketoglutarate (CaAKG), is a naturally occurring metabolite extensively studied for its role in promoting healthy aging. The investigation revealed its capacity to ameliorate critical brain functions intrinsically linked to memory, which are demonstrably impaired in the context of Alzheimer’s disease.
The research initiative was meticulously designed to assess the efficacy of CaAKG in a range of crucial cognitive parameters relevant to Alzheimer’s pathology. Specifically, the scientists sought to ascertain whether this metabolite could enhance synaptic plasticity – the brain’s ability to form and reorganize connections – within Alzheimer’s disease models. Furthermore, they aimed to determine if CaAKG could reinstate memory-associated signaling pathways, offer protection to neurons from premature degeneration, and ultimately foster a trajectory of healthier cognitive aging. These compelling findings signal a paradigm shift in medical strategy, moving towards geroprotective interventions that directly target the aging process rather than adopting a piecemeal approach to disease management.
"The revelations from our research underscore the immense potential of compounds associated with longevity in addressing the complex challenges posed by Alzheimer’s disease," stated Professor Kennedy, reflecting on the study’s implications. "Our work suggests that naturally occurring and inherently safe substances like CaAKG could, in the future, serve as valuable complements to existing therapeutic strategies aimed at safeguarding the brain and mitigating the progression of memory loss. Given that alpha-ketoglutarate is a molecule already present within our biological systems, interventions targeting these endogenous pathways may inherently carry reduced risks and possess broader applicability. This opens up the exciting prospect of a robust new framework for delaying cognitive decline and promoting sustained brain health throughout the aging process."
The experimental evidence gathered demonstrated a marked improvement in the communication mechanisms between brain cells in models recapitulating Alzheimer’s disease. CaAKG was observed to facilitate the repair of weakened signaling pathways between neurons, a crucial step in restoring associative memory, which represents one of the earliest cognitive faculties to be compromised by the disease. The research also noted that alpha-ketoglutarate levels tend to diminish naturally with advancing age, suggesting that replenishing this molecule could represent a highly promising strategy for bolstering brain health over time and potentially reducing the susceptibility to neurodegenerative disorders.
Delving deeper into the molecular underpinnings of CaAKG’s beneficial effects on learning and brain health, the research team focused on a fundamental neurobiological process known as long-term potentiation (LTP). LTP is critical for the strengthening of synaptic connections between neurons, forming the biological basis for learning and the consolidation of long-term memories. In Alzheimer’s disease, this vital process is severely compromised. The study’s findings indicated that CaAKG effectively restored LTP to levels comparable to those observed in healthy brain function.
Further investigation revealed that CaAKG stimulates autophagy, a crucial cellular "housekeeping" mechanism within the brain responsible for clearing out damaged proteins and cellular debris, thereby maintaining neuronal integrity and function. The molecule appears to exert its effects through a novel pathway, enhancing neuronal flexibility by selectively activating L-type calcium channels and calcium-permeable AMPA receptors. Significantly, this activation bypasses NMDA receptors, which are frequently rendered dysfunctional by the accumulation of amyloid plaques, a hallmark pathology of Alzheimer’s disease.
Crucially, CaAKG demonstrated the ability to restore synaptic tagging and capture, a sophisticated cellular mechanism essential for the brain to associate disparate experiences and forge associative memories. This finding carries profound implications, suggesting that the compound’s benefits extend beyond fundamental memory recall to encompass higher-order learning capacities that are typically among the first to deteriorate in individuals with Alzheimer’s disease.
Dr. Sheeja Navakkode, the study’s lead author and a research scientist within the Healthy Longevity TRP at NUS Medicine, articulated the research team’s overarching objective: "Our primary goal was to investigate whether a compound initially explored for its potential to extend healthy lifespan could offer therapeutic benefits for Alzheimer’s disease. Unraveling the precise cellular mechanisms by which CaAKG enhances synaptic plasticity provides invaluable insights into novel approaches for preserving memory function and decelerating the aging process of the brain." The collaborative effort underscores the growing convergence of longevity science and neurodegenerative disease research, promising a new era of interventions focused on promoting fundamental healthspan.
About the Author
